HomeAI · summaries
Storia in 2 fonti
Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform
The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with pharmaceutical companies.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
techfundingnews.com
Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first — TFN
Belgian techbio Sightera raises €3M to flip AI drug discovery, training its models on treatment-resistant patient biology before designing new molecules.
- ·
tech.eu
Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform
The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with…